Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 1Q

Zyprexa sales were flat at $1.1 billion; Cymbalta sales were $709.3 million (+17%); Humalog sales were up 11% to $450.6 million; Gemzar sales were $367.8 million (-14%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 1Q

1Q Revenues: $5.0 billion (+5%)

1Q Earnings: $1.3 billion (+18%)

Comments: Product sales were $4.9 billion (+4%) in the quarter. Zyprexa sales were flat at $1.1 billion; Cymbalta sales were $709.3 million (+17%); Humalog sales were up 11% to $450.6 million; Gemzar sales were $367.8 million (-14%). U.S. revenue was up 13% to $2.9 billion. Revenue outside the U.S. was down 4% to $2.2 billion, due to the impact of foreign exchange. Collaboration and other revenue was $155.2 million (+58%), primarily due to the inclusion of Erbitux revenue as a result of the ImClone acquisition. Lilly recognized $94.1 million for Erbitux, comprised of collaboration revenue of $68.0 million and product sales of $26.1 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters